Business Description
ProKidney Corp
NAICS : 541714
SIC : 8731
ISIN : KYG7S53R1049
Share Class Description:
MEX:PROK: Ordinary Shares - Class ADescription
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 82.25 | |||||
| Equity-to-Asset | -2.62 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -144 | |||||
| 3-Year EPS without NRI Growth Rate | -58.6 | |||||
| 3-Year FCF Growth Rate | -130.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.09 | |||||
| 9-Day RSI | 72.48 | |||||
| 14-Day RSI | 74.21 | |||||
| 6-1 Month Momentum % | -11.56 | |||||
| 12-1 Month Momentum % | -86.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.94 | |||||
| Quick Ratio | 14.94 | |||||
| Cash Ratio | 14.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 31.5 | |||||
| Shareholder Yield % | 7.5 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -7.48 | |||||
| ROIC % | -465.9 | |||||
| ROC (Joel Greenblatt) % | -456.57 | |||||
| ROCE % | -28.42 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 1.37 | |||||
| EV-to-Forward-EBIT | -0.97 | |||||
| EV-to-EBITDA | 1.42 | |||||
| EV-to-Forward-EBITDA | -0.98 | |||||
| EV-to-FCF | 1.54 | |||||
| Earnings Yield (Greenblatt) % | 72.88 | |||||
| FCF Yield % | -69.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ProKidney Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | |||
| EPS (TTM) (MXN) | -10.018 | ||
| Beta | 0 | ||
| Volatility % | 117.49 | ||
| 14-Day RSI | 74.21 | ||
| 14-Day ATR (MXN) | 0.715025 | ||
| 20-Day SMA (MXN) | 43.685 | ||
| 12-1 Month Momentum % | -86.8 | ||
| 52-Week Range (MXN) | 21 - 197 | ||
| Shares Outstanding (Mil) | 63.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ProKidney Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ProKidney Corp Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
ProKidney Corp Frequently Asked Questions
What is ProKidney Corp(MEX:PROK)'s stock price today?
The current price of MEX:PROK is MXN44.55. The 52 week high of MEX:PROK is MXN197.00 and 52 week low is MXN21.00.
When is next earnings date of ProKidney Corp(MEX:PROK)?
The next earnings date of ProKidney Corp(MEX:PROK) is 2024-08-09 Est..
Does ProKidney Corp(MEX:PROK) pay dividends? If so, how much?
ProKidney Corp(MEX:PROK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers